Literature DB >> 11175813

Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

A Cerutti1, E C Kim, S Shah, E J Schattner, H Zan, A Schaffer, P Casali.   

Abstract

Chronic lymphocytic leukemia (CLL) is associated with impaired immunoglobulin (Ig) class-switching from IgM to IgG and IgA, a defect that leads to recurrent infections. When activated in the presence of leukemic CLL B cells, T cells rapidly up-regulate CD30 through an OX40 ligand and interleukin 4 (IL-4)-dependent mechanism. These leukemia-induced CD30+ T cells inhibit CD40 ligand (CD40L)-mediated S mu-->S gamma and S mu-->S alpha class-switch DNA recombination (CSR) by engaging CD30 ligand (CD30L), a molecule that interferes with the assembly of the CD40-tumor necrosis factor receptor-associated factor (TRAF) complex in nonmalignant IgD+ B cells. In addition, engagement of T cell CD30 by CD30L on neoplastic CLL B cells down-regulates the CD3-induced expression of CD40L. These findings indicate that, in CLL, abnormal CD30-CD30L interaction impairs IgG and IgA production by interfering with the CD40-mediated differentiation of nonmalignant B cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11175813      PMCID: PMC4621971          DOI: 10.1038/84254

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  49 in total

1.  Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.

Authors:  C Kurts; F R Carbone; M F Krummel; K M Koch; J F Miller; W R Heath
Journal:  Nature       Date:  1999-03-25       Impact factor: 49.962

2.  Postthymic development of CD28-CD8+ T cell subset: age-associated expansion and shift from memory to naive phenotype.

Authors:  M M Nociari; W Telford; C Russo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia.

Authors:  D de Totero; G Reato; F Mauro; A Cignetti; S Ferrini; A Guarini; M Gobbi; C E Grossi; R Foa
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

4.  The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites.

Authors:  A Schaffer; A Cerutti; S Shah; H Zan; P Casali
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

5.  CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis.

Authors:  L E Van den Hove; S W Van Gool; P Vandenberghe; M A Boogaerts; J L Ceuppens
Journal:  Leukemia       Date:  1998-10       Impact factor: 11.528

6.  Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction.

Authors:  A Sampalo; G Navas; F Medina; C Segundo; C Cámara; J A Brieva
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Identification and characterization of an IkappaB kinase.

Authors:  C H Régnier; H Y Song; X Gao; D V Goeddel; Z Cao; M Rothe
Journal:  Cell       Date:  1997-07-25       Impact factor: 41.582

8.  B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.

Authors:  L Trentin; R Zambello; R Sancetta; M Facco; A Cerutti; A Perin; M Siviero; U Basso; M Bortolin; F Adami; C Agostini; G Semenzato
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

9.  T cell helper defect in patients with chronic lymphocytic leukemia.

Authors:  N Chiorazzi; S M Fu; G Montazeri; H G Kunkel; K Rai; T Gee
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

10.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

View more
  15 in total

1.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

2.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 3.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

Review 4.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.

Authors:  Joanne Fanelli Panus; Craig A Smith; Caroline A Ray; Terri Davis Smith; Dhavalkumar D Patel; David J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

6.  Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF.

Authors:  Weifeng Xu; Paul A Santini; Allysia J Matthews; April Chiu; Alessandro Plebani; Bing He; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells.

Authors:  Andrea Cerutti; Hong Zan; Edmund C Kim; Shefali Shah; Elaine J Schattner; András Schaffer; Paolo Casali
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

8.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

9.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.